Posts

Posted on

Green Dot to Collaborate with Google Pay to Offer Plex Accounts

Green Dot to Collaborate with Google Pay to Offer Plex Accounts

PASADENA, Calif.–(BUSINESS WIRE)–
Green Dot Corp. (NYSE: GDOT), a financial technology and registered bank holding company, today announced plans to work with Google Pay to offer Plex Accounts to customers: a safe, simple and helpful new option for transacting and managing their money.

“We are excited to integrate Green Dot’s safe and seamless financial tools into the intuitive user experience of Google Pay,” said Dan Henry, CEO of Green Dot. “This is another great milestone in our mission to deliver products and functionality that have the greatest impact, and that put safe, simple, value-driven banking and payments in the hands of more people and businesses.”

As part of the collaboration, Green Dot customers will be able to open and manage digital bank accounts through Google Pay, as well as access spending insights and financial search features designed to help them stay on top of their finances and manage their money more effortlessly.

“People are increasingly looking for ways to simply and securely manage their money,” said Felix Lin, vice president of Payments Ecosystems at Google. “We’re excited to expand our partnerships with new banks like Green Dot to introduce smarter bank accounts that will help their customers open their accounts, manage their finances and stay on top of their spending all from within Google Pay.”

The new product, which will be rolled out in 2021, will bring together Google Pay’s expertise in consumer tech and secure digital infrastructure and Green Dot Bank’s existing banking infrastructure and financial expertise. Accounts will be FDIC-insured.

For more detail on today’s launch, visit bit.ly/35HKiCC. For more information on Green Dot’s Banking as a Service, visit www.greendot.com/business.

About Green Dot

Green Dot Corporation (NYSE: GDOT) is a financial technology and registered bank holding company committed to transforming the way people and businesses manage and move money, and making financial wellbeing and empowerment more accessible for all.

Green Dot’s proprietary technology enables faster, more efficient electronic payments and money management, powering intuitive and seamless ways for people to spend, send, control and save their money. Through its retail and direct bank, Green Dot offers a broad set of financial products to consumers and businesses including debit, prepaid, checking, credit and payroll cards, as well as robust money processing services, tax refunds, cash deposits and disbursements. The company’s Banking as a Service (“BaaS”) platform enables a growing list of America’s most prominent consumer and technology companies to design and deploy their own customized banking and money movement solutions for customers and partners in the US and internationally.

Founded in 1999 and headquartered in Pasadena, CA, Green Dot has served more than 33 million customers directly, and now operates primarily as a “branchless bank” with more than 90,000 retail distribution locations nationwide. Green Dot Bank is a subsidiary of Green Dot Corporation and member of the FDIC. For more information about Green Dot’s products and services, please visit https://www.greendot.com.

Alison Lubert, [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Technology Mobile/Wireless Finance Software Banking

MEDIA:

Logo
Logo
Posted on

AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020

AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020

Presentations support CALQUENCE efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukemia

Emerging pipeline shows promise in novel targets and mechanisms to treat resistant and aggressive blood cancers

WILMINGTON, Del.–(BUSINESS WIRE)–
AstraZeneca will present new research aimed at addressing key unmet needs facing patients with blood cancers at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held virtually from 5 to 8 December 2020.

The Company will present 27 abstracts spanning five medicines and potential new medicines and eight different hematology conditions that demonstrate the Company’s commitment to advancing hematology research and treatments for patients living with hematologic malignancies.

Key data presentations include:

  • A pooled analysis of data from four trials – ELEVATE TN, ASCEND, ACE-CL-001 and 15-H-0016 – expanding on the cardiovascular safety profile of CALQUENCE (acalabrutinib) monotherapy treatment for patients with chronic lymphocytic leukemia (CLL)
  • Extended follow-up data from the pivotal Phase II ACE-LY-004 trial that support long-term treatment with CALQUENCE in adult patients with relapsed or refractory mantle cell lymphoma (MCL)
  • Data on CALQUENCE in combination with venetoclax and either obinutuzumab or rituximab in patients with CLL, showing a safety profile consistent with previous trials with high complete responses and undetectable minimal residual disease rates after a median follow-up of 26.9 months, with minimal to no drug-drug interactions in the Phase Ib ACE-CL-003 trial
  • First-in-human data from the potential new medicine B-cell maturation antigen (BCMA)-targeted antibody drug conjugate, MEDI2228, presenting data on safety and efficacy at all dose levels in relapsed or refractory multiple myeloma
  • Data showing pre-clinical evidence of overcoming resistance in relapsed or refractory MCL from the dual BCL2/XL inhibitor, AZD4320, which blocks the anti-apoptotic effect of BCL2 and BCLXL
  • Phase I data from the anti-inducible co-stimulator anti-ICOS monoclonal antibody, MEDI-570, demonstrating promising early clinical activity in poor-risk refractory and heavily pretreated patients with angioimmunoblastic T-cell lymphoma
  • Multiple studies on roxadustat, the first in a new class of medicines evaluating its clinical effectiveness and safety profile in both the dialysis dependent and non-dialysis dependent anemia of CKD patient populations
  • Data on roxadustat assessing efficacy in anemia secondary to lower-risk myelodysplastic syndrome (MDS) regardless of baseline factors. In approximately one in three patients MDS leads to acute myeloid leukemia1

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “Our data at ASH this year continue to support CALQUENCE as a well-tolerated treatment with impressive efficacy and safety across multiple blood cancers, reinforcing physicians’ confidence in treating patients with CALQUENCE over the long term. Data at the meeting will also explore CALQUENCE combinations with commonly used therapies, showing potential across a variety of regimens in chronic lymphocytic leukemia to best suit the unique needs of each patient.”

José Baselga, Executive Vice President, Oncology R&D, said: “As we rapidly expand our presence in hematology, we are focused on identifying novel targets and mechanisms of action that can address the most urgent unmet needs across various hematological malignancies. Our early portfolio at this year’s ASH clearly demonstrates our commitment to following the science in combating treatment-resistant and rare blood cancers.”

Key AstraZeneca presentations during the 62nd ASH Annual Meeting and Exposition

Lead author

  

Abstract title

 

Presentation details

CALQUENCE (acalabrutinib)

 

 

Brown, JR

 

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with CLL

 

Abstract #3146

Oral and Poster Abstracts

Monday, 7 December

7am–3:30pm PST

Wang, M

 

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory MCL: Long-Term Efficacy and Safety Results from a Phase 2 Study

 

Abstract #2040

Oral and Poster Abstracts

Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma

Sunday, 6 December

7am– 3:30pm PST

Woyach, JA

 

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory CLL

 

Abstract #1312

Oral and Poster Abstracts

CLL: Therapy, excluding Transplantation

Saturday, 5 December

7am – 3:30pm PST

Davids, MS

 

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab for Frontline Treatment of CLL

 

Abstract #3141

Oral and Poster Abstracts

CLL: Therapy, excluding Transplantation

Monday, 7 December

7am – 3:30pm PST

Munir, T

 

Cost-effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated CLL

 

Abstract #2510

Oral and Poster Abstracts

Health Services Research—Malignant Conditions

Sunday, 6 December

7am – 3:30pm PST

Roxadustat

  

 

Henry, D

 

Oral Roxadustat Efficacy in Anemia Secondary to Lower-risk MDS Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

 

Abstract #1277

Oral and Poster Abstracts

MDS — Clinical Studies

Saturday, 5 December

7am – 3:30pm PST

Provenzano, R

 

Pooled Efficacy and Cardiovascular Analysis of Roxadustat Compared with Placebo in Anemia Correction in Chronic Kidney Disease Patients Not on Dialysis

 

Abstract #1671

Oral and Poster Abstracts

Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron

Sunday, 6 December

7am – 3:30pm PST

Fishbane, S

 

Pooled Efficacy and Cardiovascular Safety Results of Roxadustat Compared with Epoetin Alfa in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

 

Abstract #749

Oral and Poster Abstracts

Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron

Saturday, 5 December

7am – 3:30pm PST

Early Stage Pipeline

  

 

Kumar, S

 

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

 

Abstract #179

Oral and Poster Abstracts

Myeloma/Amyloidosis: Therapy, excluding Transplantation

Saturday, 5 December

12–1:30pm PST

Li, Y

 

 

AZD4320 is a Novel and Potent BCL-2/XL Dual Inhibitor in Targeting Aggressive MCL

 

Abstract #2094

Oral and Poster Abstracts

Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents

Sunday, 6 December

7am – 3:30pm PST

Chavez, J

 

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) and Angioimmunoblastic T-cell Lymphoma (AITL) (NCI-9930)

 

Abstract #1151

Oral and Poster Abstracts

Hodgkin Lymphoma and T/NK Cell Lymphoma

Saturday, 5 December

7am – 3:30pm PST

INDICATION AND USAGE

CALQUENCE is a Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

CALQUENCE is also indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

IMPORTANT SAFETY INFORMATION ABOUT CALQUENCE® (acalabrutinib) capsules

Serious and Opportunistic Infections

Fatal and serious infections, including opportunistic infections, have occurred in patients with hematologic malignancies treated with CALQUENCE.

Serious or Grade 3 or higher infections (bacterial, viral, or fungal) occurred in 19% of 1029 patients exposed to CALQUENCE in clinical trials, most often due to respiratory tract infections (11% of all patients, including pneumonia in 6%). These infections predominantly occurred in the absence of Grade 3 or 4 neutropenia, with neutropenic infection reported in 1.9% of all patients. Opportunistic infections in recipients of CALQUENCE have included, but are not limited to, hepatitis B virus reactivation, fungal pneumonia, Pneumocystis jiroveci pneumonia, Epstein-Barr virus reactivation, cytomegalovirus, and progressive multifocal leukoencephalopathy (PML). Consider prophylaxis in patients who are at increased risk for opportunistic infections. Monitor patients for signs and symptoms of infection and treat promptly.

Hemorrhage

Fatal and serious hemorrhagic events have occurred in patients with hematologic malignancies treated with CALQUENCE. Major hemorrhage (serious or Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3.0% of patients, with fatal hemorrhage occurring in 0.1% of 1029 patients exposed to CALQUENCE in clinical trials. Bleeding events of any grade, excluding bruising and petechiae, occurred in 22% of patients.

Use of antithrombotic agents concomitantly with CALQUENCE may further increase the risk of hemorrhage. In clinical trials, major hemorrhage occurred in 2.7% of patients taking CALQUENCE without antithrombotic agents and 3.6% of patients taking CALQUENCE with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with CALQUENCE. Monitor patients for signs of bleeding.

Consider the benefit-risk of withholding CALQUENCE for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Cytopenias

Grade 3 or 4 cytopenias, including neutropenia (23%), anemia (8%), thrombocytopenia (7%), and lymphopenia (7%), developed in patients with hematologic malignancies treated with CALQUENCE. Grade 4 neutropenia developed in 12% of patients. Monitor complete blood counts regularly during treatment. Interrupt treatment, reduce the dose, or discontinue treatment as warranted.

Second Primary Malignancies

Second primary malignancies, including skin cancers and other solid tumors, occurred in 12% of 1029 patients exposed to CALQUENCE in clinical trials. The most frequent second primary malignancy was skin cancer, reported in 6% of patients. Monitor patients for skin cancers and advise protection from sun exposure.

Atrial Fibrillation and Flutter

Grade 3 atrial fibrillation or flutter occurred in 1.1% of 1029 patients treated with CALQUENCE, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients. The risk may be increased in patients with cardiac risk factors, hypertension, previous arrhythmias, and acute infection. Monitor for symptoms of arrhythmia (e.g., palpitations, dizziness, syncope, dyspnea) and manage as appropriate.

ADVERSE REACTIONS

The most common adverse reactions (≥ 20%) of any grade in patients with relapsed or refractory MCL were anemia,* thrombocytopenia,* headache (39%), neutropenia,* diarrhea (31%), fatigue (28%), myalgia (21%), and bruising (21%). The most common Grade ≥ 3 non-hematological adverse reaction (reported in at least 2% of patients) was diarrhea (3.2%).

*Treatment-emergent decreases (all grades) of hemoglobin (46%), platelets (44%), and neutrophils (36%) were based on laboratory measurements and adverse reactions.

Dose reductions or discontinuations due to any adverse reaction were reported in 1.6% and 6.5% of patients, respectively. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 4.8% of patients.

The most common adverse reactions (≥ 30%) of any grade in patients with CLL were anemia,* neutropenia,* thrombocytopenia,* headache, upper respiratory tract infection, and diarrhea.

*Treatment-emergent decreases (all grades) of hemoglobin, platelets, and neutrophils were based on laboratory measurements and adverse reactions.

In patients with previously untreated CLL exposed to CALQUENCE, fatal adverse reactions that occurred in the absence of disease progression and with onset within 30 days of the last study treatment were reported in 2% for each treatment arm, most often from infection. Serious adverse reactions were reported in 39% of patients in the CALQUENCE plus obinutuzumab arm and 32% in the CALQUENCE monotherapy arm, most often due to events of pneumonia (7% and 2.8%, respectively).

Adverse reactions led to CALQUENCE dose reduction in 7% and 4% of patients in the CALQUENCE plus obinutuzumab arm (N=178) and CALQUENCE monotherapy arm (N=179), respectively. Adverse events led to discontinuation in 11% and 10% of patients, respectively. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 3.9% and 2.8% of patients in the CALQUENCE combination arm and monotherapy arm, respectively.

In patients with relapsed/refractory CLL exposed to CALQUENCE, serious adverse reactions occurred in 29% of patients. Serious adverse reactions in > 5% of patients who received CALQUENCE included lower respiratory tract infection (6%). Fatal adverse reactions within 30 days of the last dose of CALQUENCE occurred in 2.6% of patients, including from second primary malignancies and infection.

Adverse reactions led to CALQUENCE dose reduction in 3.9% of patients (N=154), dose interruptions in 34% of patients, most often due to respiratory tract infections followed by neutropenia, and discontinuation in 10% of patients, most frequently due to second primary malignancies followed by infection. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 1.3% of patients who received CALQUENCE.

DRUG INTERACTIONS

Strong CYP3A Inhibitors: Avoid co-administration with a strong CYP3A inhibitor. If a strong CYP3A inhibitor will be used short-term, interrupt CALQUENCE.

Moderate CYP3A Inhibitors: When CALQUENCE is co-administered with a moderate CYP3A inhibitor, reduce CALQUENCE dose to 100 mg once daily.

Strong CYP3A Inducers: Avoid co-administration with a strong CYP3A inducer. If a strong CYP3A inducer cannot be avoided, increase the CALQUENCE dose to 200 mg approximately every 12 hours.

Gastric Acid Reducing Agents: If treatment with a gastric acid reducing agent is required, consider using an H2-receptor antagonist or an antacid. Take CALQUENCE 2 hours before taking an H2-receptor antagonist. Separate dosing with an antacid by at least 2 hours.

Avoid co-administration with proton pump inhibitors. Due to the long-lasting effect of proton pump inhibitors, separation of doses may not eliminate the interaction with CALQUENCE.

SPECIFIC POPULATIONS

Based on findings in animals, CALQUENCE may cause fetal harm and dystocia when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

Pregnancy testing is recommended for females of reproductive potential prior to initiating CALQUENCE therapy. Advise female patients of reproductive potential to use effective contraception during treatment with CALQUENCE and for at least 1 week following the last dose of CALQUENCE.

It is not known if CALQUENCE is present in human milk. Advise lactating women not to breastfeed while taking CALQUENCE and for at least 2 weeks after the final dose.

Avoid administration of CALQUENCE in patients with severe hepatic impairment. Dose modifications are not required for patients with mild or moderate hepatic impairment.

Please see full Prescribing Information, including Patient Information.

CALQUENCE

CALQUENCE(acalabrutinib) is a next-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK). CALQUENCE binds covalently to BTK, thereby inhibiting its activity.2,3 In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.2

As part of an extensive clinical development program, AstraZeneca and Acerta Pharma are currently evaluating CALQUENCE in more than 20 company-sponsored clinical trials. CALQUENCEis being developed for the treatment of multiple B-cell blood cancers including CLL, MCL, diffuse large B-cell lymphoma, Waldenström macroglobulinemia, follicular lymphoma, and other hematologic malignancies.

Roxadustat

Roxadustat is a first in a new class of investigational medications that has the potential to promote erythropoiesis through increased endogenous production of erythropoietin; improved iron absorption, transport and mobilization; and downregulation of hepcidin, which helps to overcome the negative impact of inflammation on hemoglobin synthesis and red blood cell production. The roxadustat NDA for the treatment of anemia in CKD in both NDD and DD is under review by the US Food and Drug Administration with a decision expected in Q4 2020. Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

AstraZeneca and FibroGen Inc. (FibroGen) are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the US, China and other markets in the Americas and in Australia/New Zealand, as well as Southeast Asia. Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa.

AstraZeneca in hematology

Leveraging its strength in oncology, AstraZeneca has established hematology as one of four key oncology disease areas of focus. The Company’s hematology franchise includes two medicines approved by the US Food and Drug Administration and a robust global development program for a broad portfolio of potential blood cancer treatments. Acerta Pharma serves as AstraZeneca’s hematology research and development arm. AstraZeneca partners with like-minded science-led companies to advance the discovery and development of therapies to address unmet need.

AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers.

By harnessing the power of six scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, Antibody Drug Conjugates, Epigenetics, and Cell Therapies – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

References

  1. American Cancer Society. What Are Myelodysplastic Syndromes? Available online. Accessed October 2020.
  2. CALQUENCE (acalabrutinib) [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; 2019.
  3. Wu J, Zhang M & Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(21).

Media Inquiries

Michele Meixell, +1 302 885 2677

Brendan McEvoy, +1 302 885 2677

KEYWORDS: Delaware United States North America

INDUSTRY KEYWORDS: Research Diabetes Cardiology Biotechnology Health Pharmaceutical General Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Jack Nathan Health to Begin Opening 50 New Medical Clinics in Mexico

Jack Nathan Health to Begin Opening 50 New Medical Clinics in Mexico

Signed addendum to Master Service Agreement with Walmartadds significant growth potential for Jack Nathan Health in Mexico

TORONTO–(BUSINESS WIRE)–
Jack Nathan Medical Corp. (TSXV:JNH) (“Jack Nathan Health” “JNH” or the “Company”) announced today that its subsidiary JNH Medico Mexico S.A. DE C.V., a provider of primary care medical clinics located in Walmart® Supercentres and other Walmart Mexico formats under the Jack Nathan Health® brand, has signed an addendum to its ongoing Master Service Agreement (“MSA”), which now specifies and directs Jack Nathan to construct 50 new locations throughout the country. This plan for rapid expansion begins immediately with the first 8 locations scheduled to open by the end of December 2020.

The clinics provide much needed healthcare services in Mexican communities where many chronic diseases go undiagnosed and untreated due to a shortage of affordable options for quality healthcare services. Jack Nathan Health clinics are now sending out home COVID-19 tests authorized by the Mexican Health Authority to patients nationally. The costs of these tests are prepaid and include a telemedicine appointment with one of Jack Nathan Health’s physicians. Jack Nathan Health’s facilities will swiftly and dramatically increase access to professional and convenient care in the communities where they operate.

“We are pleased to now begin a phase of significant growth in Mexico within Walmart. Preventative healthcare has always been a necessity in Mexico and taking a holistic approach to health comes with many benefits,” said Laura Camacho, Country Manager of Jack Nathan Health Mexico. “The new clinics, coupled with our existing telemedicine offering, bring innovative solutions and a better overall health experience throughout the country.”

With the addition of 50 new clinics, Jack Nathan Health will have 56 total clinics in Mexico, all corporately owned and operated. Rapid expansion in Walmart Mexico is fueled by modular, cost-effective construction, that only takes days and requires no capital expenditure from Jack Nathan Health, resulting in immediate revenue growth and a short timeframe to achieve accretive clinic operations.

This is also an important step toward fulfilling on Jack Nathan Health’s vision to be one of the leading integrated primary healthcare provider in the world, as well as generating better health outcomes for citizens globally. Jack Nathan Health is well positioned in Canada and now Mexico to assist in the distribution and immunization of potential COVID-19 vaccines.

“Applying our Jack Nathan healthcare expertise to communities that are in need is a truly gratifying moment in our Company’s history,” said George Barakat CEO & Co-Founder of Jack Nathan Health. “We’ve flipped the healthcare model by creating a patient-first experience. Now, with accelerated growth in Mexico, in a manner that reduces upfront costs and the administrative burden on doctors, Jack Nathan Health clinics clearly demonstrate the value of our offering. More importantly, families in these communities will now have access to a more consistent, quality, and affordable healthcare experience. It gives the citizens of Mexico the opportunity to begin their Circle of Health Care™ journeys. These new clinics, with telemedicine support, will be an integral part of our next phase of expansion with Walmart Mexico.”

Jack Nathan Health clinics in Mexico, are enhanced with our new telemedicine platform which increases access for patients throughout the country. Adding 50 new clinics significantly improves digital access to Jack Nathan Health Mexico locations with a growing group of medical professionals in our network.

About Jack Nathan Medical Corp.

Jack Nathan Medical Corp., operating as Jack Nathan Health®, is one of Canada’s largest health care networks. Jack Nathan Health® is an innovative health care company that is improving access for millions of patients by co-locating physician and ancillary medical services conveniently located inside Walmart® stores.

Jack Nathan Health® provides an exceptional level of patient care, made possible through patient-centric physicians, a variety of medical services, technology and programs, designed to put patients first. Our mission is to provide everyone access to the finest quality retail medical centres, with both in-clinic physicians and digital telemedicine, so you and your loved ones can “Live Your Best Life”.

Jack Nathan Health® was established in 2006 and continues to expand its international footprint, delivering exceptional, state-of-the-art, turn-key medical centres in 76 Walmart locations across Canada including British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec, as well as six locations in Mexico.

For more information, visit www.jacknathanhealth.com or www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to Jack Nathan are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to them, and are subject to certain risks, uncertainties and assumptions Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative and other judicial, regulatory, political and competitive developments; the economic and business impact of Covid19 and operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

IR:

David Berman, CFO, [email protected]

or

Mark Kuindersma, LodeRock Advisors, [email protected]

PR & Marketing:

Jennifer Usher, Director Marketing & Communications, [email protected]

KEYWORDS: Mexico Central America North America Canada

INDUSTRY KEYWORDS: Practice Management Nursing Managed Care Health Infectious Diseases Hospitals Discount/Variety Retail

MEDIA:

Logo
Logo
Posted on

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020 where management will participate in 1×1 meetings. A fireside chat held with Seres management will be made available on the News and Events section of the Company’s website on November 23, 2020.
  • 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 2, 2020. Management will participate in 1×1 meetings.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

PR Contact

Lisa Raffensperger

[email protected]

IR Contact

Carlo Tanzi, Ph.D.

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Other Health Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo
Posted on

Volt Executives Named to Staffing Industry Analysts’ 2020 “Global Power 150 – Women in Staffing” List

Volt Executives Named to Staffing Industry Analysts’ 2020 “Global Power 150 – Women in Staffing” List

ORANGE, Calif.–(BUSINESS WIRE)–
Volt Information Sciences, Inc. (NYSE-AMERICAN: VOLT), a global provider of staffing services, today announced that both Linda Perneau, President & Chief Executive Officer, and Lori Schultz, Chief Global Solutions Officer, were named by Staffing Industry Analysts to the “Global Power 150 – Women in Staffing” list.

In its sixth year, the Global Power 150 List highlights 100 influential women from the Americas, and 50 globally, who have made significant contributions to the success of their companies and the staffing industry ecosystem. As the first female CEO in Volt’s long history, Ms. Perneau took the company helm in late 2018, achieving improved financial performance, revamping business lines, and gaining operational efficiencies. Ms. Schultz’s oversight includes the company’s managed service provider, Volt Consulting Group, as well as Volt International and the company’s Arctern subsidiary, which provides shared services support from India.

“We are honored to be recognized by SIA,” said Linda Perneau, Volt’s President and Chief Executive Officer. “Being named to this list in particular is a source of pride for both Lori and I. As veteran female executives, we have devoted our careers to the business of workforce solutions – but we have never lost sight of the need to make the workplace work for women. Volt understands the vital role the staffing industry plays in recruiting and retaining women at all levels and stages of their careers. We firmly believe more diverse teams perform and deliver better, and sincerely appreciate SIA’s acknowledgment of the powerful women who excel and promote that ideal.”

About Volt Information Sciences, Inc.

Volt Information Sciences, Inc. is a global provider of staffing services (traditional time and materials-based as well as project-based). Our staffing services consist of workforce solutions that include providing contingent workers, personnel recruitment services, and managed staffing services programs supporting primarily administrative, technical, information technology, light-industrial and engineering positions. Our managed staffing programs involve managing the procurement and on-boarding of contingent workers from multiple providers. Volt services global industries including aerospace, automotive, banking and finance, consumer electronics, information technology, insurance, life sciences, manufacturing, media and entertainment, pharmaceutical, software, telecommunications, transportation, and utilities. For more information, visit www.volt.com.

Investor Relations Contact:

Volt Information Sciences, Inc.

[email protected]

Joe Noyons

Three Part Advisors

[email protected]

817-778-8424

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Professional Services Human Resources

MEDIA:

Posted on

New study: People living longer in retirement, signals need for lifetime income strategies

New study: People living longer in retirement, signals need for lifetime income strategies

Some retirees outliving savings, others spending less than they’ve accumulated

DES MOINES, Iowa–(BUSINESS WIRE)–
Guaranteed income strategies have emerged as underutilized methods to not only help people save for retirement but also provide a stream of income to sustain them during potentially longer life spans. The new study from the Longevity Project in collaboration with Principal Financial Group® and the Stanford Center on Longevity, explores the implications of longevity in retirement and potential policy and industry recommendations. According to the white paper, Lifetime Income to Support Longer Life: Retirement Innovation and the New Age of Longevity, people entering retirement tend to either overspend and withdraw funds at unsustainable rates, or they underspend, denying themselves basic needs because they’re afraid of running out of money.1

“There’s been a significant improvement in life expectancy over time,” said Sri Reddy, senior vice president, Retirement and Income Solutions at Principal®. “At the same time, many retirees are significantly underestimating how many years they’ll spend in retirement. This uncertainty, combined with variables including declining pension benefits and rising costs, can make it difficult to plan for spending one’s assets in retirement.”

The average American turning age 65 today can expect to live 40% longer than someone who turned 65 in 1950.2 Furthermore, the number of Americans retiring every day has more than doubled over the last 20 years.3

“While helping Americans save enough for retirement must continue to be a critical priority, our research points to the next frontier for retirement—helping Americans spend their retirement savings in a sensible, measured way,” said Ken Stern, chair of the Longevity Project. “Income annuities have emerged as a viable and immediately realizable vehicle to help many Americans generate guaranteed lifetime income. However, expanding the role of guaranteed lifetime income will require a concerted effort to educate consumers.”

Solving the puzzle of longer life and longer retirement

According to a Longevity Project – Morning Consult poll featured in the study, only a small percentage of retirees and pre-retirees (7%) are counting on annuities to be an important part of their retirement portfolio. This compares to much higher reliance on Social Security benefits (64%), personal savings and investments (38%), and 401(k) or 403(b) plans offered by employers (35%). The new white paper attributes these low adoption rate to several factors:

  • Consumers may not see income annuities as simple or easy to understand. Variable annuities and indexed annuities have a reputation of being more complex and sometimes more expensive.
  • Consumers don’t want to “lose” money by putting it in an annuity and possibly dying before getting their money back. They may value access to their money over the promise of not running out of money.
  • Financial professionals are still warming up to annuities. Some may lack understanding of how annuities work and may not position them with clients.
  • Retirement plan sponsors are the gatekeepers of America’s defined contribution plans—the retirement savings vehicle for millions of Americans. Since very few plans currently offer guaranteed lifetime income options in their plan’s lineup, people may just not be familiar with them.

Product innovations such as automatic enrollment and automatic escalation and the growth of target date funds have helped many Americans to save for retirement. But at retirement, many find themselves in a financial world with little to guide them on how to spend down their retirement savings, facing a wide variety of complicated decisions and few ways to protect themselves financially if their retirement lasts longer than average. These factors underscore the value of working with financial professionals.

“With the passage of the SECURE Act last year, we took an important first step towards creating a framework for guaranteed retirement income solutions,” said Reddy. “This study shows us there is a real need for industry, plan sponsors, financial professionals and policy makers to collaborate at new levels to increase access to lower-cost income annuities and similar lifetime income solutions so American workers may have a more secure retirement and more confidence that they will not outlive their resources.”

As a part of its continued commitment to promote financial security, Principal works with financial professionals to provide the resources employers need to help workers prepare for retirement. Now more than ever, it is important to help people develop a plan that supports them feeling confident about the future — and guaranteed income is a key strategy that can aid in that effort. Principal has an innovative in-plan solution that provides guaranteed income for the rest of the plan participant’s life, which is even more valuable as people live longer than previous generations and spend more years in retirement.

About Principal®

Principal helps people and companies around the world build, protect and advance their financial well-being through retirement, insurance and asset management solutions that fit their lives. Our employees are passionate about helping clients of all income and portfolio sizes achieve their goals – offering innovative ideas, investment expertise and real-life solutions to make financial progress possible. To find out more, visit us at principal.com.

About the Longevity Project

We foster research and public conversation to build awareness of the implications of longer life, and bring together leaders from business, government, and the social sector to plan for the transitions in healthcare, retirement planning, the future of work and more. Together with our lead content collaborator, the Stanford Center on Longevity and other leading universities, think tanks and media organizations, our goal is to support a new awareness of the longevity challenge and support change so that people around the world can live healthier, more secure and more fulfilled lives.

The subject matter in this communication is educational only and provided with the understanding that Principal® is not rendering legal, accounting, investment advice or tax advice. You should consult with appropriate counsel or other advisors on all matters pertaining to legal, tax, investment or accounting obligations and requirements.

Stanford Center is not an affiliate of any company of the Principal Financial Group.

Investment and Insurance products are:

• Not Insured by the FDIC or Any Federal Government Agency

• Not a Deposit or Other Obligation of, or Guaranteed by, A Bank or Any Bank Affiliate

• Subject to Investment Risks, Including Possible Loss of the Principal Amount Invested

Guarantees are based upon the claims-paying ability of the issuing insurance company.

©2020 Principal Financial Services, Inc. Insurance products issued by Principal National Life Insurance Co (except in NY) and Principal Life Insurance Co. Plan administrative services offered by Principal Life. Principal Funds, Inc. is distributed by Principal Funds Distributor, Inc. Securities offered through Principal Securities, Inc., 800-247-1737, member SIPC and/or independent broker/-dealers. Referenced companies are members of the Principal Financial Group®, Des Moines, IA 50392.

Principal, Principal and symbol design and Principal Financial Group are trademarks and service marks of Principal Financial Services, Inc., a member of the Principal Financial Group.

© 2020 Principal Financial Services, Inc.

1415138-112020

1 Longevity Project interview with Steve Vernon, March 6, 2020

2 The Longevity Project in collaboration with Principal Financial Group and the Stanford Center on Longevity. The Lifetime Income to Support Longer Life: Retirement Innovation and the New Age of Longevity white paper, 2020.

3 U.S. Census Bureau / Deutsche Bank https://finance.yahoo.com/news/americans-retiring-increasing-pace-145837368.html

Lonnetta Ragland, [email protected], 515-878-1504

KEYWORDS: United States North America Iowa

INDUSTRY KEYWORDS: Other Consumer Insurance Finance Seniors Consulting Banking Professional Services Consumer Other Professional Services

MEDIA:

Logo
Logo
Posted on

Visa Launches Research Center Committed to Promoting and Advancing Global Economic Equity and Inclusivity

Visa Launches Research Center Committed to Promoting and Advancing Global Economic Equity and Inclusivity

  Visa Economic Empowerment Institute will conduct and develop unique research and generate powerful insights to enhance the global payments ecosystem

SAN FRANCISCO–(BUSINESS WIRE)–
Visa Inc. (NYSE: V) today announced the launch of the Visa Economic Empowerment Institute (VEEI), a center of excellence for research and public-private dialogue on payments policy, committed to promoting and advancing equitable economic empowerment of individuals, businesses and societies around the world.

The VEEI will develop new research and insights designed to inform long-term policy within the global payments ecosystem, and promote the value of digital payments and global networks to advance inclusion and drive economic growth. VEEI will serve as a forum for policymakers, regulators, non-governmental organizations and international organizations to convene and collaborate on policies to rebuild and grow the global economy.

“Visa’s unparalleled global network and perspective on economic trends will allow VEEI to develop novel insights on the payments ecosystem and provide actionable solutions for improving and enhancing communities,” said Al Kelly, chairman and CEO of Visa. “The creation of VEEI is our next step toward removing barriers and creating more accessible economic opportunities for everyone, everywhere.”

Dr. Barbara Kotschwar, a Georgetown University professor and former specialist at the World Bank, will serve as the VEEI’s Executive Director. She will lead a team of Fellows, who are subject matter experts in payments, central banking, development finance, international trade, cybersecurity and other key issues. The Fellows will leverage Visa’s vast information resources and technology capabilities to analyze problems and develop policy recommendations to bring real solutions to communities around the world. Bill Sheedy, senior advisor to Visa CEO Al Kelly, will chair the Institute.

“As our world becomes more complex and interconnected, it is paramount that we close gender, global development, ethnicity, and other inclusion gaps to achieve digital connectivity and access to global markets for all,” said Dr. Kotschwar. “The Institute will provide a platform for public and private actors to work together collectively to increase economic empowerment, trade and global connectivity.”

The Visa Economic Empowerment Institute will focus on three strategic pillars to further its mission:

  • Fostering Digital Equity and Inclusion, which will address societal issues, inclusive economic growth, financial inclusion, and micro, small and medium enterprises (MSME) recovery and resilience.
  • Unlocking Growth through Trade, which will address the factors that encourage greater digital and cross-border trade.
  • Imagining an Open Future for Payments, which will address the future of money, societal and cross-border issues and innovations that are shaping the way people pay and are paid, and MSME recovery.

In connection with the launch, the VEEI released a set of foundational position papers, highlighting some of the key contextual challenges its pillars of research will focus on, including:

  • Fostering Digital Equity and Inclusion: The pandemic has accelerated several years of digital transformation into months, reinforcing the importance of digital connectivity and highlighting systemic inequities around access and barriers to usage. For example, while 93% of the world’s population lives within physical reach of mobile broadband or internet connections, nearly half (3.6 billion people) do not use it.i
  • Unlocking Growth Through Trade: Trade agreements have not kept pace with advances in technology and economic growth in the digital economy. With few firm commitments on digital trade, protectionism is on the rise, threatening MSME growth and their connections to the broader digital economy.
  • Imagining an Open Future for Payments: Payment innovations are increasing and demand a new approach to cybersecurity protections and financial services on new payment platforms.

VEEI is uniquely positioned to lead conversations between the public and private sectors and future publications will reflect this dialogue. To learn more about VEEI and to read the foundational position papers, please visit https://usa.visa.com/sites/visa-economic-empowerment-institute.html.

About Visa

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device, for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, visa.com/blog and @VisaNews.

i Report of the Secretary-General. Roadmap for Digital Cooperation. June 2020. https://www.un.org/en/content/digital-cooperation-roadmap/assets/pdf/Roadmap_for_Digital_Cooperation_EN.pdf

Lindy Mockovak

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Finance Banking Other Philanthropy Professional Services Philanthropy

MEDIA:

Posted on

Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer

Pivotal Trial Expected to be Initiated During 1Q21

HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a Phase 3 trial design for AVB-500 in platinum resistant ovarian cancer (PROC). The global, randomized, double-blind, placebo-controlled adaptive trial is designed to evaluate efficacy and tolerability of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel.  

“We look forward to advancing AVB-500 into a pivotal Phase 3 trial in platinum resistant ovarian cancer, following the promising results from our Phase 1b trial and productive conversations with the FDA,” said Gail McIntyre, Ph.D., Chief Executive Officer of Aravive. “With agreement from the FDA that our preclinical and clinical pharmacology programs are now complete, we anticipate that this trial, if successful, could support the submission of a biologics license application to the FDA. We plan to initiate the trial in the first quarter of 2021, with an interim analysis expected a year later.”

The pivotal, adaptive Phase 3 trial is expected to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy. This global trial is planned to be conducted at approximately 100 sites in the U.S. and Europe. The primary endpoint for the trial is progression free survival, and secondary endpoints include overall survival, objective response rate, duration of response, quality of life, clinical benefit rate, and pharmacokinetic and pharmacodynamic profile. Prospectively defined interim analyses will investigate treatment differences in patients who have previously received bevacizumab versus those who have not and will explore the biomarkers identified in the Phase 1b trial in an effort to test the hypotheses generated from the Phase 1b data. Based on the interim analyses, the trial can be adapted to include only those patients who have not previously been treated with bevacizumab and/or whose baseline serum biomarker results meet the identified threshold.

About AVB-500

AVB-500 is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian cancer. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. AVB-500 is currently being evaluated in clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals.

About Aravive

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selected 15 mg/kg as the dose for the Phase 3 trial. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year. For more information, please visit www.aravive.com.

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended), express or implied, such statements regarding advancing AVB-500 into a pivotal Phase 3 trial during first quarter 2021, the trial supporting the submission of a biologics license application to the FDA, conducting an interim analysis a year later, enrollment of approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy, the trial being conducted at approximately 100 sites in the U.S. and Europe. Forward-looking statements are based on current beliefs and assumptions, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement as a result of various factors, including, but not limited to, risks and uncertainties related to: our ability to initiate a pivotal trial during first quarter 2021, the trial supporting the submission of a biologics license application to the FDA, our ability to conduct an interim analysis a year later, as planned, our ability to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy as planned, our ability to conduct the trial at approximately 100 sites in the U.S. and Europe as planned, our ability to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma as planned later this year, the impact of COVID-19 on the Company’s clinical strategy, clinical trials, supply chain and fundraising, the Company’s ability to expand development into additional oncology indications, the Company’s dependence upon AVB-500, AVB-500’s ability to have favorable results in clinical trials and ISTs, the clinical trials of AVB-500 having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in the Company’s clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that AVB-500 may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that the Company may encounter difficulties in manufacturing AVB-500; if AVB-500 is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing the Company’s intellectual property rights; the Company’s reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, recent Current Reports on Form 8-K and subsequent filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Media:

Sheryl Seapy, W2O
[email protected]
(213) 262-9390

Investors:

Luke Heagle, W2O
[email protected]
(910) 726-1372



Posted on

Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference

LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that management will participate in a fireside chat at the 3rd Annual Evercore ISI Health CONx Conference on 3 December, 2020 from 08.00 – 8.20 am ET.

A live audio webcast of the fireside chat will be available on the events section of Freeline’s website.  An archived replay will be available on the Company’s website for a period of 90 days after the conference.

About Freeline

Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.

Forward-Looking Statements

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company’s strategies, financing plans, and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the development of the Company’s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work; the Company’s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of infectious diseases in the U.S., U.K. or EU, including the COVID-19 pandemic, to disrupt the Company’s clinical trial pipeline; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company’s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience which could result in delays in the development or commercialization of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programs or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Further information:

United States

LifeSci Advisors

Dan Ferry
+1 (617) 430 7576
[email protected]

Europe

JW Communications

Julia Wilson
+44 (0) 7818 430877
[email protected] 



Posted on

DeFi Project KingSwap Completes Migration from Uniswap to its Own Liquidity & Farming Pools

After generating millions in transaction volume on Uniswap, KingSwap’s staking rewards, NFTs, and fiat conversions are all available on its platform

Singapore, Nov. 19, 2020 (GLOBE NEWSWIRE) — (via Blockchain Wire) DeFi project KingSwap (https://www.kingswap.io/) today announced it has completed its migration from Uniswap to its own platform’s liquidity and farming pools. Earlier this month, KingSwap achieved $4 million USD in transaction volume in its first three days on Uniswap. Now, KingSwap’s DEX features are available directly through its website https://www.kingswap.exchange. 

The first regulated* DeFi project out of Singapore, KingSwap is a high-yield liquidity platform that offers extensive staking rewards, digital collectibles, and fiat conversions. An evolution of Uniswap, KingSwap provides user-friendly features that provide real-time benefits in terms of price curves and contributor rewards. 

“We’re pleased with the quick progress our team has made in migrating KingSwap’s liquidity and farming pools from Uniswap to KingSwap,” said Malcolm Tan, KingSwap advisor. “We are grateful to Uniswap for providing us the early traction and visibility we needed to generate an enthusiastic user base, and look forward to building upon this with exciting NFT launches and platform enhancements in the coming weeks.” 

KingSwap’s NFTs give their owners loyalty rewards from $KING tokens issued. The project sold out several batches of its exclusive ‘Knight Token’ NFTs and ‘Queen Sparkle’ NFTs, which provide owners access to $KING airdrops.  Daily airdrops have already been distributed to all NFT holders (with over 200% ROI). The resale market for these NFTs is already robust, with some resellers already achieving returns of over 150 percent within a span of a few days. 

Prior to KingSwap’s public launch on October 30, venture capital firms and cryptocurrency investors participated in KingSwap’s private fundraising round, helping the project quickly exceed its 1000 ETH soft cap to raise over $20 million USD in funding and liquidity support. KingSwap’s backers include Plutus VC, Hashstreet VC, Alpha Sigma Capital, Tradecraft Capital, and 7CC. 

KingSwap was founded by a team of experienced leaders in banking, finance, and crypto, including Dr. Anish Mohammed, who has advised and worked for companies including HSBC, Lloyds, and Zurich, and was an early advisor to Ripple and Ocean Protocol; Dunstan Teo, Chief Architect of the Fido Protocol and President of Sanctum Pte Ltd.; and Ho Chin Shin, who previously worked as a director at Standard Chartered Bank; Nomura, Japan’s largest investment bank; and the Bank of Singapore. 

KingSwap’s advisors include Venture Capitalist Dr. Giampaolo Parigi (PhD); Professor Alex Nascimento (MBA), Faculty and Co-Founder, Blockchain at UCLA; Michael Terpin, Founder and CEO of Transform Group and Co-Founder of BitAngels; Lionel Iruk, Esq.(J.D), Dr. Robert Choi (PhD), and Frank D.(MBA). 

To learn more about KingSwap, join the KingSwap Telegram group or follow the project on Twitter. 

ABOUT KINGSWAP
KingSwap (https://www.kingswap.io/) is a DeFi project based out of Singapore that is introducing a liquidity pool platform with fiat conversions. KingSwap’s high-yield liquidity platform offers extensive staking rewards, digital collectibles, and fiat conversions. An evolution of Uniswap, KingSwap provides user-friendly features that provide real-time benefits in terms of price curves and contributor rewards.  



Media Contact: Transform Group, [email protected]